News Releases

In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.

Month Year

Month Year

Get News Alerts by Email

Jun 5, 2016

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer

Patients Receiving ALIMTA-KEYTRUDA-Carboplatin Combination Demonstrate Response Rate of 71 Percent
- Photos 1
Jun 5, 2016

Genomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients

Four New Analyses of SEER Registry Provide Additional Evidence that Oncotype DX Accurately Predicts Patient Outcomes in Node-negative and Node-positive Breast Cancer and Reinforce Its Value in Older Women
- Photos 1
Jun 5, 2016

Daratumumab (DARZALEX®) Combination Therapy Significantly Extended Progression-Free Survival in Previously Treated Patients with Multiple Myeloma

- Phase 3 data from the MMY3004 (CASTOR) trial to be featured in the Plenary Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA4)
Jun 5, 2016

Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC)

- Secondary objective demonstrated one-year overall survival rate in 32 percent of patients identified with high expression of delta-like protein 3 (DLL3) SCLC
Jun 4, 2016

OBI Pharma Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting

Results from Phase II/III Clinical Trials Show Improvement in Subset of Patients who Developed an Immune Response to Vaccination

Show per page

For more trade show news go to www.vporoom.com